Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Safety and PK Study of ANXV in Healthy Males
NCT04850339Phase 1Completed
- Sponsor
- Annexin Pharmaceuticals AB
- Start
- Dec 2020
- Primary completion
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of annexin a5 in retinal vein occlusion (RVO) (4 arms), sponsored by Annexin Pharmaceuticals AB. Primary endpoints: Frequency of adverse events, Seriousness of adverse events and 1 more. Started Dec 2020; status: completed.
02
Drugs
annexin a5
03
Conditions
retinal vein occlusion (RVO)
Beyond the preview
Go deeper on NCT04850339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04850339.